Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Hepion Pharmaceuticals, Inc. (HEPA : NSDQ)
 
 • Company Description   
Hepion Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis and chronic hepatitis virus infection. The Company's lead drug candidate CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Hepion Pharmaceuticals Inc., formerly known as ContraVir Pharmaceuticals Inc., is based in Edison, New Jersey.

Number of Employees: 20

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.75 Daily Weekly Monthly
20 Day Moving Average: 273,418 shares
Shares Outstanding: 76.23 (millions)
Market Capitalization: $56.85 (millions)
Beta: 1.40
52 Week High: $2.32
52 Week Low: $0.61
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.11% -13.41%
12 Week -23.90% -16.34%
Year To Date -34.58% -20.15%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
399 THORNALL STREET FIRST FLOOR
-
EDISON,NJ 08837
USA
ph: 732-902-4000
fax: 732-902-4100
skilmer@hepionpharma.com http://www.hepionpharma.com
 
 • General Corporate Information   
Officers
Robert Foster - Chief Executive Officer
Gary S. Jacob - Chairman; Board of Directors
John Cavan - Chief Financial Officer
John Brancaccio - Director
Arnold Lippa - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 426897104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 76.23
Most Recent Split Date: 6.00 (0.01:1)
Beta: 1.40
Market Capitalization: $56.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.67
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -34.79
12/31/21 - -31.38
09/30/21 - -30.66
ROA
03/31/22 - -31.19
12/31/21 - -28.54
09/30/21 - -27.68
Current Ratio
03/31/22 - 14.34
12/31/21 - 11.88
09/30/21 - 14.90
Quick Ratio
03/31/22 - -
12/31/21 - 11.88
09/30/21 - 14.90
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.11
12/31/21 - 1.20
09/30/21 - 1.32
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©